Bracanat 150mg Tablet

About Bracanat 150mg Tablet

Bracanat 150mg Tablet contains Olaparib, a targeted anticancer medication that belongs to the PARP (Poly ADP-ribose Polymerase) inhibitor class. It is primarily used in the treatment of pancreatic cancer and prostate cancer by blocking the PARP enzyme, which cancer cells rely on to repair damaged DNA. This action helps slow the growth and spread of cancer cells while improving treatment outcomes. Bracanat 150mg Tablet may be prescribed alone or in combination with other anticancer medications depending on the patient's condition and treatment plan. The dosage is determined by the treating oncologist based on the patient's medical history, overall health, and response to therapy, and patients should not alter or discontinue treatment without medical advice. Before starting treatment, inform your doctor if you have liver, kidney, lung, or heart disease, and attend regular follow-up appointments and blood tests to monitor blood cell counts and treatment response. Bracanat 150mg Tablet is not recommended during pregnancy or breastfeeding, as it may harm an unborn baby. Women of childbearing potential should use effective contraception during treatment, while men should avoid donating sperm during therapy and for at least three months after the final dose. When purchasing Bracanat 150mg Tablet, always use a licensed pharmacy and a valid prescription to ensure you receive an authentic product. Patients should consult their healthcare provider before considering any substitute or alternative medication, as treatment decisions should be based on individual medical needs. With appropriate medical supervision, Bracanat 150mg Tablet offers an effective targeted treatment option for eligible patients with pancreatic and prostate cancer.